Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Expert Interviews

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Youtube

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Optimizing Treatment Strategies for Advanced Upper GI Cancers

Video Series

Megan’s Journey With HER2+ Upper GI Cancer

Video content above is prompted by the following:

Experts discuss treatment strategies for advanced upper gastric cancers, focusing on biomarker testing, treatment options, and managing adverse effects.

Experts discuss Robert’s journey with HER2- upper gastrointestinal (GI) cancer, highlighting key treatment approaches and challenges.

HER2-  Upper GI Cancer

Experts discuss frontline treatment options for advanced upper gastric adenocarcinoma, molecular testing methods, challenges encountered, and how test results influence the choice of systemic therapy for patients.

Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy

Experts discuss the role of reflex testing in ensuring accurate and timely treatment selection, the challenges it may present, and how it can be integrated with next-generation sequencing (NGS) to provide a comprehensive molecular profile while minimizing delays.

Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment

Experts discuss the relevance of PD-L1 CPS in predicting immunotherapy efficacy, other complementary biomarkers, the benefits of adding nivolumab to a FOLFOX regimen, and how the CheckMate 649 trial and its recent 5-year update have influenced the use of nivolumab in combination with chemotherapy for advanced gastric and gastroesophageal adenocarcinomas.

The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer

Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.

Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

Experts discuss how to approach prognosis and treatment goals with a patient, considering their family history of gastric cancer and advanced-stage disease.

Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach

Experts discuss Megan’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment strategies and challenges.

Experts discuss the PD-L1 combined positive score (CPS) and its influence on treatment decisions as well as the clinical significance of a high CPS in guiding the use of immune checkpoint inhibitors such as pembrolizumab in HER2-positive gastric cancer.

Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

Experts discuss the factors supporting the choice of trastuzumab deruxtecan following disease progression and its mechanism of action in addressing resistance to prior HER2-targeted therapy and provide insights on the updated analysis from the DESTINY-Gastric02 Trial.

ADCs in HER2+ Gastric Cancer

Experts discuss specific biomarkers or clinical features that would prompt earlier consideration of trastuzumab deruxtecan or other HER2-directed therapies.

Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer

Experts discuss how microsatellite-stable (MSS) status in this case affects the expected benefit of pembrolizumab and whether its continued use beyond progression in combination with other agents would be considered.

Considerations for Combinations Beyond Progression in Upper GI Cancer

Experts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.

Exploring Next-Line Options in HER2- MSS Gastric Cancer

Megan’s Journey With HER2+ Upper GI Cancer

EP: 1.HER2- Upper GI Cancer

EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy

EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment

EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer

EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach

EP: 7.Megan’s Journey With HER2+ Upper GI Cancer

EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

EP: 9.ADCs in HER2+ Gastric Cancer

EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer

EP: 11.Considerations for Combinations Beyond Progression in Upper GI Cancer

EP: 12.Exploring Next-Line Options in HER2- MSS Gastric Cancer